US 12,453,780 B2
Monoclonal antibodies specific for fibroblast growth factor receptor 4 (FGFR4) and methods of their use
Javed Khan, Derwood, MD (US); Sivasubramanian Baskar, Ellicott City, MD (US); Rimas J. Orentas, Seattle, WA (US); Dimiter S. Dimitrov, Pittsburgh, PA (US); Zhongyu Zhu, Frederick, MD (US); and Tai Chi Cheuk, Germantown, MD (US)
Assigned to The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Filed by The U.S.A., as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Filed on Jun. 23, 2021, as Appl. No. 17/355,703.
Application 17/355,703 is a division of application No. 15/761,398, granted, now 11,078,286, previously published as PCT/US2016/052496, filed on Sep. 19, 2016.
Claims priority of provisional application 62/221,045, filed on Sep. 20, 2015.
Prior Publication US 2021/0324090 A1, Oct. 21, 2021
Int. Cl. C07K 16/46 (2006.01); A61K 39/395 (2006.01); A61K 47/68 (2017.01); A61K 47/69 (2017.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01)
CPC A61K 47/6849 (2017.08) [A61K 39/39558 (2013.01); A61K 47/6803 (2017.08); A61K 47/68031 (2023.08); A61K 47/6911 (2017.08); A61P 35/00 (2018.01); C07K 16/2863 (2013.01); C07K 2317/622 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01)] 20 Claims
 
1. A chimeric antigen receptor (CAR) comprising:
a monoclonal antibody that binds fibroblast growth factor receptor 4 (FGFR4), or antigen-binding fragment thereof, comprising a variable heavy (VH) domain and a variable light (VL) domain, wherein the VH domain of the antibody comprises the complementarity determining region 1 (CDR), CDR2, and CDR3 sequences of SEQ ID NO: 3 and the VL domain of the antibody comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 4;
a transmembrane domain; and
a signaling domain,
wherein the VH domain CDR1, CDR2 and CDR3 sequences respectively comprise residues 26-33, 52-59 and 98-111 of SEQ ID NO: 3, and the VL domain CDR1, CDR2 and CDR3 sequences respectively comprise residues 27-32, 50-52 and 88-98 of SEQ ID NO: 4.